Cargando…

CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Urothelial carcinoma of the bladder (UCB) is a common genitourinary cancer. Advanced UCB, defined as muscle-invasive and lymph node-involving, is linked to poor outcomes. CA125 is a well-known tumor marker for ovarian cancer and can be used as a diagnostic marker for advanced UCB. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hsuan-Jen, Hu, Rouh-Mei, Chen, Hung-Chih, Lin, Chung-Chih, Lee, Chi-Yu, Chou, Che-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913454/
https://www.ncbi.nlm.nih.gov/pubmed/36765770
http://dx.doi.org/10.3390/cancers15030813
_version_ 1784885431335124992
author Lin, Hsuan-Jen
Hu, Rouh-Mei
Chen, Hung-Chih
Lin, Chung-Chih
Lee, Chi-Yu
Chou, Che-Yi
author_facet Lin, Hsuan-Jen
Hu, Rouh-Mei
Chen, Hung-Chih
Lin, Chung-Chih
Lee, Chi-Yu
Chou, Che-Yi
author_sort Lin, Hsuan-Jen
collection PubMed
description SIMPLE SUMMARY: Urothelial carcinoma of the bladder (UCB) is a common genitourinary cancer. Advanced UCB, defined as muscle-invasive and lymph node-involving, is linked to poor outcomes. CA125 is a well-known tumor marker for ovarian cancer and can be used as a diagnostic marker for advanced UCB. This meta-analysis reviewed published studies in English and Chinese on serum CA125 for advanced UCB. One thousand five hundred seventy patients from 14 studies were analyzed. The diagnostic odds ratio was 8.138, and the area under the receiver operating characteristic curve was 0.797. Serum CA125 may help distinguish advanced UCB from non-advanced UCB patients. CA125 may help clinicians plan the treatment of UCB. ABSTRACT: Background: Urothelial carcinoma of the bladder (UCB) is the second most common genitourinary cancer. This study aims to assess the diagnostic accuracy of CA125 in advanced UCB. Methods: We searched prevalent studies in PubMed, the Cochrane Library, Scopus, Embase, the Web of Science China National Knowledge Infrastructure database, and Wanfang data before October 2022. Pooled sensitivity, specificity, and summary receiver operating characteristics were used to assess the diagnostic value of CA125. Results: One thousand six hundred forty-one patients from 14 studies were analyzed. UCB stage T3–4N1 was defined as advanced UCB in ten studies; T2–4 was used in three studies; and N1M1 in one study. Patients’ age was between 21 to 92, and 21% to 48.6% of patients were female. The pooled sensitivity was 0.695 (95% confidence interval (CI): 0.426–0.875). The pooled specificity was 0.846 (95% CI: 0.713–0.924). The diagnostic odds ratio was 8.138 (95% CI: 4.559–14.526). The AUC was 0.797. Conclusion: CA125 may provide significant diagnostic accuracy in identifying muscle-invasive, lymph node-involved, and distant metastatic tumors in patients with urothelial carcinoma of the bladder. Limited studies have been conducted on the prognostic role of CA125. More studies are needed for a meta-analysis on the prognostic role of CA125 in UCB.
format Online
Article
Text
id pubmed-9913454
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134542023-02-11 CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis Lin, Hsuan-Jen Hu, Rouh-Mei Chen, Hung-Chih Lin, Chung-Chih Lee, Chi-Yu Chou, Che-Yi Cancers (Basel) Systematic Review SIMPLE SUMMARY: Urothelial carcinoma of the bladder (UCB) is a common genitourinary cancer. Advanced UCB, defined as muscle-invasive and lymph node-involving, is linked to poor outcomes. CA125 is a well-known tumor marker for ovarian cancer and can be used as a diagnostic marker for advanced UCB. This meta-analysis reviewed published studies in English and Chinese on serum CA125 for advanced UCB. One thousand five hundred seventy patients from 14 studies were analyzed. The diagnostic odds ratio was 8.138, and the area under the receiver operating characteristic curve was 0.797. Serum CA125 may help distinguish advanced UCB from non-advanced UCB patients. CA125 may help clinicians plan the treatment of UCB. ABSTRACT: Background: Urothelial carcinoma of the bladder (UCB) is the second most common genitourinary cancer. This study aims to assess the diagnostic accuracy of CA125 in advanced UCB. Methods: We searched prevalent studies in PubMed, the Cochrane Library, Scopus, Embase, the Web of Science China National Knowledge Infrastructure database, and Wanfang data before October 2022. Pooled sensitivity, specificity, and summary receiver operating characteristics were used to assess the diagnostic value of CA125. Results: One thousand six hundred forty-one patients from 14 studies were analyzed. UCB stage T3–4N1 was defined as advanced UCB in ten studies; T2–4 was used in three studies; and N1M1 in one study. Patients’ age was between 21 to 92, and 21% to 48.6% of patients were female. The pooled sensitivity was 0.695 (95% confidence interval (CI): 0.426–0.875). The pooled specificity was 0.846 (95% CI: 0.713–0.924). The diagnostic odds ratio was 8.138 (95% CI: 4.559–14.526). The AUC was 0.797. Conclusion: CA125 may provide significant diagnostic accuracy in identifying muscle-invasive, lymph node-involved, and distant metastatic tumors in patients with urothelial carcinoma of the bladder. Limited studies have been conducted on the prognostic role of CA125. More studies are needed for a meta-analysis on the prognostic role of CA125 in UCB. MDPI 2023-01-28 /pmc/articles/PMC9913454/ /pubmed/36765770 http://dx.doi.org/10.3390/cancers15030813 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Lin, Hsuan-Jen
Hu, Rouh-Mei
Chen, Hung-Chih
Lin, Chung-Chih
Lee, Chi-Yu
Chou, Che-Yi
CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title_full CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title_fullStr CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title_full_unstemmed CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title_short CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
title_sort ca125 for the diagnosis of advanced urothelial carcinoma of the bladder: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913454/
https://www.ncbi.nlm.nih.gov/pubmed/36765770
http://dx.doi.org/10.3390/cancers15030813
work_keys_str_mv AT linhsuanjen ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis
AT hurouhmei ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis
AT chenhungchih ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis
AT linchungchih ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis
AT leechiyu ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis
AT choucheyi ca125forthediagnosisofadvancedurothelialcarcinomaofthebladderasystematicreviewandmetaanalysis